Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines
This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.IC: NIAIDNIH Ref. No.: E-195-2014/0Advantages: Broad/universal protection against influenza virusesDoes not require reformulating vaccine each year as is currently necessary with vaccines available on the marketCan potentially provide protection against novel influenza viruses that may arise in the future, including potentially pandemic influenza virusesApplications: VaccinesProvider Technology ID: 3081Updated On: Nov 22, 2016Date Published: Tuesday, November 22, 2016Provider Classifications: Publications: Patent Application: PCT/US2015/02984362/014,821Patent Authority: PCTUS2016-12-01 00:00:002016-12-01 00:00:00Licensing Contacts: LPM Address: --United StatesLead Inventor: Inventor IC: NIAIDInventor Lab URL: http://irp.nih.gov/pi/jeffery-taubenbergerLPM FIrst Name: JenishLPM Last Name: ...
The first European consensus on vaccination in patients with MS has been developed by the European Committee for Treatment and Research in Multiple Sclerosis and the European Academy of Neurology.Medscape Medical News
Deaths among people who have been fully vaccinated remain rare, but older adults and those with compromised immune systems are at much higher risk.
The CDC released data on Thursday showing that unvaccinated Americans are 11 times as likely to die of COVID-19 than vaccinated people, and six times as likely to be infected.
The lower dose of Biktarvy is now approved for pediatric patients weighing at least 14 kg and for adults.FDA Approvals
- CBSSports.com site: media |...
The WHO lists antimicrobial resistance as a top ten global health threat, saying that by 2050 it will kill more people than cancer. Could novel vaccines provide new ways to defeat superbugs?
DR MARTIN SCURR: This is almost certainly chronic rhinosinusitis, where the lining of the nose and sinuses become infected or inflamed by allergy.
The U.S. Food and Drug Administration (FDA) will allow fully vaccinated Americans to 'mix and match' COVID-19 vaccines and booster shots.
- CBSSports.com site: media | arena:...